PQM conducted an assessment of the medicine quality assurance and quality control systems in Rwanda during November 9-13, 2009. Medicine quality assurance remains to be developed in Rwanda: the country has neither a medicine regulatory authority (MRA) nor a national medicine quality control laborato...ry – the two key institutions to ensure the quality, safety, and efficacy of medicines. The MOH Pharmacy Taskforce (PTF) is to be commended however for successfully controlling the pharmaceutical market to the extent that there is no informal medicines market in Rwanda. Based on its findings, the assessment team expects Rwanda to be able to make great strides in evidence-based medicines quality assurance in the short to medium term, provided it receives adequate technical assistance and financial support.
more
Social Mobilization in the Freetown Peninsula during the Ebola Epidemic 2014-2015
MMWR. Recommendations and Reports:
December 16, 2005 / 54(RR15);49-55
This report is produced by the UNDAC Team in Lima. It is developed in collaboration with the partners of the National Humanitarian Network (RHN). It covers the period from 27 to 30 March 2017. The next report will be issued around April 3, 2017
The International Journal of Tuberculosis and Lung Disease 21(5) DOI: 10.5588/ijtld.16.0518
Oxford Policy Management (OPM) - APW with UNAIDS (thru TSF)
Vaincre le Sida par Tous, une Riposte pour Tous
Le Plan Stratégique National de Lutte contre le Sida (PSN) 2018-2022 sera le cadre unique pour tous les acteurs de la lutte contre le sida au Sénégal. Il constitue la référence pour la programmation des activités aux niveaux national et régio...nal, et sera l’outil indispensable pour l’harmonisation et l’alignement des partenaires. Ce plan traduit la vision et les engagements du Gouvernement du Sénégal à maintenir les acquis et à orienter la riposte vers l’élimination du sida en utilisant toutes les opportunités et ressources, aussi bien domestiques qu’internationales.
more
Suivi de la déclaration politique sur le VIH de 2011 – Sénégal 2014
Programme commun des nations unies sur le VIH/SIDA
The extensive use of antimicrobials in human and veterinary medicine in recent years has accelerated the emergence and spread of resistant microorganisms. This situation has been worsened by the lack of investment in developing new effective antibiotics. The severity of the consequences is clear to ...see: it is estimated that each year, drug-resistant infections result in at least 25 000 patient deaths and cost the EU EUR 1,5 billion in healthcare costs and through loss of productivity
more
This document provides guidance on the application of non-pharmaceutical countermeasures to minimise the spread of the 2019 novel coronavirus (2019-nCoV) in the population. Some of the measures proposed refer specifically to certain phases of the epidemic (containment or mitigation phases), and can ...be adapted depending on the assessed severity/impact of the infection. Other measures are valid for all phases of an epidemic.
The guidance is based on the current knowledge of the 2019-nCoV and evidence available on other viral respiratory pathogens, mainly the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), the Middle East Respiratory Syndrome-related coronavirus (MERS-CoV) and seasonal or pandemic influenza viruses.
more
Le secrétariat du RSI à l’OMS a développé un outil pour les missions d’EEC qui mesure les aptitudes du pays à prévenir, détecter et répondre rapidement aux menaces de santé publique, conformément aux exigences du RSI (2005). Cet outil est également utilisé pour l’exercice d’auto-...évaluation réalisé par le pays, préalablement à l’EEC. Les résultats ainsi obtenus permettent de préparer un plan d’action national multisectoriel destiné à renforcer la mise en œuvre du RSI (2005).
more
Reporting period January 2015 – December 2015
Bucharest, April 2016
Supporting the food and agriculture sectors in implementing the Global Action Plan on Antimicrobial Resistance to minimize the impact of antimicrobial resistance
Research Article
Karo et al. BMC Infectious Diseases 2014, 14:148 http://www.biomedcentral.com/1471-2334/14/148